Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Nivolumab for BRAF V600 mutation– negative advanced melanoma – first line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CTLA-4 Antigens; Melanoma; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Survival Rate Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32015000119 Date abstract record published 23/02/2015 |